Share with your CISO
Pharma’s compliance professionals are already running AI daily, and they’ve stopped waiting for Canadian regulation to catch up. At the PCC Canada Pharma and MedTech Compliance conference in Toronto, panelists from Amgen, AstraZeneca, and Boehringer Ingelheim reported that 74% of delegates use AI governance self-regulation frameworks in the absence of binding law, with over 80% planning to increase AI investment in compliance activities. Canada’s proposed AI legislation, Bill C-27, died in parliamentary prorogation in 2025, leaving organizations to build their own guardrails across privacy, monitoring, and automated decision-making.
What this means for your business
The governance gap here is not a Canadian anomaly. Any CISO operating in a jurisdiction where AI-specific legislation is still in draft, meaning most of them, is already in this position whether they’ve named it or not. The question isn’t whether your organization has AI in compliance workflows; the 74% daily-use figure from a room of pharma compliance professionals suggests it does. The question is whether your internal framework was built intentionally or accumulated by default, and those two things produce very different audit trails.
The most useful signal from the Boehringer Ingelheim framing is the instruction to stop treating AI governance as a separate discipline and instead augment existing structures, privacy impact assessments, vendor due diligence, data classification policies, with AI-specific criteria. Organizations that built parallel AI ethics boards and standalone AI review committees in 2023 are discovering those structures don’t connect to where the decisions actually get made. Bolting AI considerations onto the processes that already have teeth is operationally cheaper and, critically, more likely to catch a bad output before it becomes a reportable incident.
The dominant risk these practitioners identified is not a breach or a malicious actor. It’s employees acting on AI outputs that are inaccurate, biased, or incomplete, which is an output quality and human oversight problem, not a perimeter security problem. CISOs who’ve scoped AI risk primarily as a data exfiltration concern are looking at the wrong tail. If your AI risk register doesn’t have line items for hallucination-driven compliance decisions and over-reliance on automated monitoring agents, the framework is incomplete. I’d revise this read if Canadian or EU enforcement actions start citing data leakage rather than faulty outputs as the primary harm vector in regulated industries.
Concept deep-dive: Principles-based AI governance
Principles-based governance sets broad behavioral commitments, transparency, accountability, human oversight, rather than prescribing specific technical controls. Think of it as building codes that specify fire safety outcomes rather than mandating a particular sprinkler brand. In AI, it matters because the technology changes faster than any rule set can track. The business tradeoff is real: principles give flexibility but require mature judgment to apply consistently, which is exactly the skills gap pharma compliance teams say they’re now racing to close.
Based on reporting from Pharma Companies Create AI Governance Frameworks, originally published 2026-07-16 11:54:00.
